FASLG and hepatitis A virus infection: Thus, pharmacological inhibition of LRH-1 may represent an interesting therapeutic option in the treatment of T-cell-dependent and FasL-mediated immunopathologies, such as hepatitis and acute Graft-versus-Host disease.